Loading the recordsβ¦
Loading the recordsβ¦

Josh Gottheimer (D-NJ) sold $1K-$15K of $ABT (Abbott Laboratories Common Stock) on Jul 18, 2025, part of 7 transactions in this filing.
How the largest positions have moved from the trade date to the most recent close.
Showing the 6 largest positions. See every transaction in the table below.
See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.
Get Free Access β| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| PARTIAL SELL | $ABT | Abbott Laboratories Common Stock | $1K-$15K | $123.67 | β | β | Jul 18, 2025 |
| SELL | $IRT | Independence Realty Trust, Inc. Common Stock | $1K-$15K | β | β | β | Jul 16, 2025 |
| PARTIAL SELL | $IBM | International Business Machines Corporation Common Stock | $1K-$15K | $259.72 | β | β | Jul 25, 2025 |
| PARTIAL SELL | $NTRA | Natera, Inc. - Common Stock | $1K-$15K | $139.92 | β | β | Jul 22, 2025 |
| SELL | $SWTX | SpringWorks Therapeutics, Inc. - common stock | $1K-$15K | $46.99 | β | β | Jul 2, 2025 |
| PARTIAL SELL | $V | Visa Inc. | $1K-$15K | $350.50 | β | β | Jul 14, 2025 |
| PARTIAL SELL | $WMT | Walmart Inc. Common Stock | $1K-$15K | $97.61 | β | β | Jul 28, 2025 |
These bills and contracts share tickers or sectors with this filing's trades.
The PrEP and PEP are Prevention Act (HR5127) mandates zero-cost coverage of HIV prevention drugs and associated lab monitoring across all US insurance programs. This early-stage bipartisan bill creates direct volume upside for Gilead ($GILD) on branded PrEP, Viatris ($VTRS) on generic PrEP, and Labcorp ($LH) on mandatory diagnostic services. Merck ($MRK) is excluded from the causal chain because its islatravir candidate is not FDA-approved and the bill only covers approved drugs.
The No Tax on Overtime for All Workers Act (HR5475) is in the earliest legislative stage β introduced and referred to the House Ways and Means Committee in September 2025. It proposes a tax deduction for overtime compensation but lacks a specified funding mechanism or revenue offset. No market-moving impact is possible at this procedural stage with zero appropriations or binding policy changes.
The Food Date Labeling Act of 2025 (S.2541) standardizes voluntary date labels but carries no appropriations, is in early-stage committee, and imposes only trivial one-time compliance costs on grocery retailers and food distributors. Near-term market impact is negligible. Real market data shows KR down -6.27% and WMT up +5.1% over 30 days, driven by macro factors entirely unrelated to this procedural bill.
HR4548 opens the tax-exempt small employer market (1.3M 501(c) organizations) to retirement plan subsidies for the first time, creating a new customer acquisition opportunity for payroll and retirement administration providers ADP and PAYX. The bill is in early legislative stages with bipartisan sponsorship.
The EATS Act of 2025 remains dormant after introduction 9 months ago, with no committee action or scheduled markups. The bill's near-zero passage probability in a Republican-controlled Senate means zero near-term market impact for grocery retailers like Walmart and Kroger.
S.2677 is an early-stage procedural bill that expands CBP's authority to share IP violation data with rights holders. It imposes minimal compliance obligations on marketplaces and carriers but has zero appropriated funding. This bill has no material market-moving potential for any company. Retail investors should ignore this legislation for trading decisions.
HR5343 would force Medicare to provide immediate 4-year coverage for FDA breakthrough devices, directly benefiting large medical device manufacturers by eliminating the current 1-3 year coverage lag. The bill passed the Ways & Means committee 37-3 but awaits floor action. Despite bearish recent price action (MDT -8.2%, ABT -11%, BDX -7.3% in 30 days), this bill represents a structural catalyst for device revenue acceleration.
HR5605, the Medical Device Nonvisual Accessibility Act, is in early committee stage with zero appropriation β a compliance mandate, not a spending bill. Home medical device makers face moderate retrofit costs but no immediate revenue impact. Market data shows medtech stocks already under broad 30-day pressure (-8% to -11%), and this bill adds a minor regulatory cost layer without near-term catalyst.
IBM has secured a $27.6M delivery order from the Department of Homeland Security for architecture engineering support, maintaining USCIS enterprise infrastructure. This contract represents a routine but significant win for IBM's government services division, reinforcing its role in federal IT modernization.
Optum Public Sector Solutions, a subsidiary of UnitedHealth Group ($UNH), secured a $1.1 billion contract from the Department of Veterans Affairs, indicating significant revenue for its parent company in the healthcare technology sector. This award aligns with legislative efforts to enhance healthcare services for veterans and modernize federal health IT infrastructure.
Free β no credit card
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter β before they hit the news.
Weekly digest β the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan Β· No credit card Β· Unsubscribe in one click
Want the live terminal too? Create a free account β
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.